DOI: 10.36347/sjams.2023.v11i02.015

Pages: 366-371

Background: Many people still lack access to health care in countries like Bangladesh, despite the country's impressive record of improvement and growth in this area. Pregnancy-related hypertension is the most prevalent medical issue. Objective: In this study our main goal is to compare the efficacy of labetalol and methyldopa in treatment of pregnancy induced hypertension. Method: This study was conducted in the Department of Obstetrics and Gynaecology, Abdul Malek Ukil Medical College, Noakhali over a period of 2 years from September 2019 to September 2021, after taking ethical committee clearance. 180 Pregnancy Induced Hypertensive women after 20 weeks of pregnancy coming to hospital over a period of 2 years on IPD basis from September 2019 to September 2012 were included as sample size. Among 180 patients of PIH, 90 were given Labetalol (group A) and 90 were given Methyldopa (group B). Results: during the study, with labetalol, the mean arterial pressure on admission was 109.48mmHg which reduced to 96.90mmHg on day 7. Reduction in MAP was statistically significant. On comparing the two drugs, MAP on admission were comparable but on day 7, significant fall in MAP was seen in patients receiving labetalol. In the present study, the mean time required to control BP in group A was 42.22 hours and in group Bit was 36.97 hours. In group A, 40% patients required a dose of 750 mg/day to achieve optimal BPcontrol. Whereas 52% patients had their BP controlled with 300mg / day. Thus the rate of spontaneous labour was more in patients treated with labetalol. Patients in both group where in both group most common side-effect observed was headache. 8% patients in Group A and 7% patients in group B had this symptom. Conclusion: The freedom from maternal and fetal side-effects, the efficient hypotensive action indicates that labetalol is suitable for use during pregnancy.